Obexelimab
mAbexperimental
Clinical trial activity
7 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02725515)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD19BINDING AGENT
B-lymphocyte antigen CD19 binding agent
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
Low affinity immunoglobulin gamma Fc region receptor II-b inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298134 ↗
- ChEMBLCHEMBL2109338 ↗
Also known as
- amg-729
- xmab5871
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06559163 | Phase 2 | Sep 17, 2024 | Zenas BioPharma (USA), LLC |
| NCT06564311 | Phase 2 | Aug 26, 2024 | Zenas BioPharma (USA), LLC |
| NCT05786573 | Phase 3 | Sep 25, 2023 | Zenas BioPharma (USA), LLC |
| NCT05662241 | Phase 3 | Sep 30, 2022 | Zenas BioPharma (USA), LLC |
| NCT02867098 | Phase 1 | Jul 1, 2016 | Parexel, Xencor |
| NCT02725476 | Phase 2 | Mar 1, 2016 | Harvard University, Xencor |
| NCT02725515 | Phase 2 | Feb 1, 2016 | ICON, PPD, Xencor |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zenas BioPharma (USA), LLC | For profit | 4 | 4 | 2 | 2022 |
| Xencor | For profit | 3 | 3 | 2 | 2016 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| ICON | For profit | 1 | 0 | 1 | 2016 |
| Parexel | For profit | 1 | 0 | 1 | 2016 |
| PPD | For profit | 1 | 0 | 1 | 2016 |
6 organizations
Page 1 / 1